Novo Nordisk (NVO) and KKR's (KKR) joint acquisition of Sylvan International Biotechnology in China was cleared by the EU's antitrust review, the European Commission said Wednesday.
The Commission said it found that the proposed transaction would not raise competition concerns as the joint venture would have "negligible activities" in the European Economic Zone.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。